Interleukin-7 Resensitizes Non-Small-Cell Lung Cancer to Cisplatin via Inhibition of ABCG2

• Autores principales: Bin Ke (Autor), Ting Wei (Autor), Yuanyuan Huang (Autor), Yuxin Gong (Autor), Gang Wu (Autor), Junfang Liu (Autor), Xiaoting Chen (Autor), Lin Shi (Autor)
• Formato: Libro
• Publicado: Hindawi Limited, 2019-01-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Treatment with cisplatin (DDP) is one of the standard therapies used to treat non-small-cell lung cancer (NSCLC) and fundamentally causes resistance in cancer cells, which eventually poses as an obstacle to the efficacy of chemotherapy in NSCLC. Efforts are on all over the world to explore a sensiti...